US Patent 9,072,857: Scope, Claims, Expiration, Orange Book Status, and Competitive Patent Landscape

US Patent 9,072,857 protects an exhalation-actuated nasal delivery device that combines a sealed nasal interface, a metered liquid aerosol generator, and an exhalation flow resistor. Its central technical concept is indirect closure of the oropharyngeal velum through pressure generated when a patient exhales against resistance. The patent is closely associated with Optinose’s exhalation delivery system technology used in XHANCE, fluticasone propionate nasal spray.

The strongest infringement position lies in devices that use all of the following elements together: a nosepiece sealing one nostril, an exhalation-actuated liquid aerosol generator, a flow resistor, and pressure-induced velum closure. A conventional nasal spray, dry-powder inhaler, nebulizer, or bilateral nasal irrigation device would not ordinarily satisfy the independent claims without additional structural features.

What does US Patent 9,072,857 cover?

US 9,072,857 covers a nasal drug-delivery device designed to improve access to regions of the nasal airway beyond the anterior nasal cavity. The device uses the patient’s exhaled breath to create a pressure differential between the mouth and nasal airway.

The core architecture has four components:

A nosepiece inserted into one nostril.
A sealing member that seals the nostril around the outlet.
A liquid aerosol generator that dispenses a metered dose during exhalation.
A flow resistor that the patient exhales against.

The pressure differential is intended to cause indirect closure of the oropharyngeal velum. Once the velum closes, exhaled gas can be directed through the nasal passages and, in certain configurations, around the posterior margin of the nasal septum and out of the opposite nostril.

This architecture differs from ordinary nasal sprays, which generally deliver a liquid plume without controlling the patient’s exhaled airflow or creating a pressure-supported pathway through the nasal cavity.

Patent identification and commercial relevance

Item	Description
Patent	US 9,072,857 B2
Title	Nasal delivery device
Technology	Exhalation delivery system for nasal administration
Patent owner/technology originator	Optinose-related patent estate
Relevant product	XHANCE fluticasone propionate nasal spray
FDA product type	Prescription nasal spray
Core mechanism	Exhalation against a flow resistor with unilateral nasal sealing
Claim categories	Device, device-plus-substance combination, indicator-equipped device
Primary commercial field	Nasal corticosteroids and other locally or systemically delivered pharmaceuticals

The patent is not limited to fluticasone, chronic rhinosinusitis, or nasal polyps. Those applications are commercially important but narrower than the patent’s principal device claims.

How do the independent claims of US 9,072,857 work?

Claim 1: core device claim

Claim 1 is the principal platform claim. It requires:

A device for delivering a substance to the nasal airway.
Delivery to one nostril through a nosepiece outlet.
A sealing member around the outlet.
A sealing member with distal and proximal ends.
Enlargement of the sealing member toward the proximal end.
Enlargement of the anterior nasal cavity region into which the nosepiece is inserted.
A liquid aerosol spray generator.
Actuation during patient exhalation.
A metered dose of substance.
A flow resistor.
Positive pressure between the oral cavity and nasal airway.
Indirect closure of the oropharyngeal velum.

The claim is cumulative. A competing device that has only an exhalation-triggered spray but lacks the specified sealing member may avoid the claim. A device with a nasal seal and flow resistor but no liquid aerosol generator may also avoid literal infringement.

The phrase "thereby indirectly achieving closure" is important. The claim does not require a mechanical valve that physically closes the velum. It requires the device to create the pressure conditions that cause physiological closure.

Claim 14: device with feedback

Claim 14 repeats the main architecture of claim 1 and adds an indicator. The indicator must provide at least one visual or audible signal when the subject exhales against the flow resistor.

This claim creates a separate infringement pathway for devices that provide compliance feedback, such as:

An audible whistle.
A pressure-triggered tone.
A light-emitting indicator.
A display confirming adequate exhalation.
A signal tied to a pressure or flow threshold.

Claim 14 may be commercially relevant because digital or electronically assisted nasal delivery platforms can satisfy the indicator limitation even when the underlying mechanical system resembles claim 1.

What do dependent claims 2 through 7 protect?

The dependent claims narrow the location and function of the flow resistor and add a bilateral nasal-flow configuration.

Claim	Added limitation	Technical significance
2	Flow resistor connected to a tubular section held between the lips	Covers a tube-in-mouth configuration
3	Flow resistor connected to a mouthpiece	Covers an integrated oral interface
4	Flow resistor fluidly connected to the nosepiece	Covers a nasal-unit architecture
5	Driving pressure sufficient to direct gas around the posterior nasal septum and out the other nostril	Covers cross-nasal flow
6	Separate outlet unit fitted to the other nostril with a second flow resistor	Covers bilateral delivery or controlled outlet resistance
7	Outlet-unit flow resistor is adjustable	Covers user or clinician adjustment of outlet resistance

Claims 5 through 7 are particularly important for devices intended to generate airflow through both nasal passages. They add functional and structural limitations that can make design-around analysis more complex.

A competing product may use unilateral delivery without a second nostril outlet. Such a product could still implicate claim 1, but claims 5 through 7 would be less likely to apply.

What substances are covered by claims 8 through 13?

Claims 8 through 13 claim combinations of the device with a substance. The listed substance categories include:

A steroid.
Oxytocin.
An anti-migraine pharmaceutical.
An anti-allergic pharmaceutical.
An anti-inflammatory pharmaceutical.

These claims do not appear limited to a particular active ingredient, concentration, formulation excipient, disease, or dosing schedule. The combination claims therefore extend the platform into multiple therapeutic areas, subject to the interpretation of "steroid," "anti-migraine pharmaceutical," and the other functional categories.

The claims can potentially cover both locally acting and systemically acting nasal therapies if the product is used with the claimed delivery device.

Relationship to fluticasone propionate

Fluticasone propionate is a corticosteroid. XHANCE therefore falls within the steroid category in claim 9 if the commercial device satisfies the remaining claim limitations.

The patent does not, based on the supplied claims, require:

Fluticasone propionate specifically.
A particular fluticasone concentration.
Treatment of nasal polyps.
Treatment of chronic rhinosinusitis.
A particular dosing frequency.
A specific spray-plume geometry.

Those limitations may appear in separate formulation, method-of-treatment, or product patents.

When does US Patent 9,072,857 lose exclusivity?

US 9,072,857 has a standard US patent-term framework based on the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. A 20-year term generally runs from the relevant earliest nonprovisional filing date, not from the grant date.[1]

Public patent databases identify the patent as an Optinose-related nasal delivery patent with priority reaching into the late 2000s. On that basis, the unadjusted expiration period is generally expected to fall in the late 2020s, subject to the patent’s recorded term adjustment.

Exclusivity issue	Assessment
Patent type	Utility patent
Patent-term rule	20 years from applicable earliest nonprovisional filing
Expected base expiration window	Late 2020s
Possible adjustment	Patent-term adjustment may extend the base date
Patent-term extension	Product-specific extension would require an eligible regulatory basis
Pediatric exclusivity	Separate FDA exclusivity, if granted, would not change the patent expiration date
Practical erosion	Continuation patents may maintain related protection after this patent expires

The exact expiration date should be determined from the USPTO patent-term adjustment record and the complete priority chain. The grant date, July 7, 2015, does not itself determine expiration.

What is the Orange Book status of US 9,072,857?

The Orange Book lists patents associated with approved drug products when the patents meet FDA listing requirements. A device patent may be listed if it claims the drug product, a formulation, or a method of using the approved drug product. FDA listing practices distinguish between patents that directly claim the approved product or use and patents that relate only to an independent delivery device.[2]

For XHANCE, the relevant Orange Book analysis must separate:

Patents directed to the fluticasone propionate formulation.
Patents directed to use in chronic rhinosinusitis or nasal polyps.
Patents directed to the exhalation delivery device.
Continuation patents with overlapping delivery-system claims.

US 9,072,857 is commercially relevant to XHANCE because the product uses the Optinose exhalation delivery system. Its precise Orange Book status, listed-use code, and expiration entry should be read from the current FDA Orange Book product record rather than inferred solely from the patent claims.

If listed against an approved product, the patent could support a Paragraph IV certification by an ANDA applicant. If not listed, an ANDA applicant may still need to address the patent through other certification or litigation strategies depending on the product and filing circumstances.

What Paragraph IV challenges could affect the patent?

A generic applicant seeking approval for an equivalent fluticasone propionate nasal product could challenge listed patents through a Paragraph IV certification. The primary arguments against US 9,072,857 would likely involve claim scope, anticipation, obviousness, noninfringement, and the distinction between a drug product and a delivery device.

Likely Paragraph IV theories

Theory	Potential argument
Noninfringement	The proposed product lacks the claimed enlarged proximal sealing member
Noninfringement	The product does not use a liquid aerosol generator actuatable during exhalation
Noninfringement	The product lacks a flow resistor
Noninfringement	The product does not create the claimed oral-to-nasal pressure differential
Invalidity	Prior art disclosed nasal sealing and exhalation resistance in combination
Invalidity	The velum-closure limitation is inherent or obvious from known nasal airflow systems
Written description	The asserted claim scope exceeds the original disclosure
Enablement	The full range of substances or devices is not enabled

A conventional fluticasone nasal spray would have a strong noninfringement position if it does not include the claimed exhalation system. An authorized generic or alternative nasal delivery platform using the same pressure-based architecture would face greater risk.

What patent litigation affects the Optinose nasal delivery estate?

The commercial patent risk is likely to arise from the broader XHANCE portfolio rather than from US 9,072,857 alone. Patent litigation in this area can involve:

Device architecture.
Nasal sealing geometry.
Exhalation flow paths.
Formulation and spray characteristics.
Methods for treating chronic rhinosinusitis.
Generic or authorized-generic fluticasone products.
Continuation patents that issue after an earlier patent is challenged.

An ANDA litigation event normally begins after a Paragraph IV notice and may trigger a 30-month FDA approval stay if statutory requirements are met. The presence of multiple related patents can produce staggered litigation and settlement outcomes.

No conclusion about infringement or validity follows from the patent grant alone. Claim construction is likely to focus on "enlarged towards the proximal end," "configured to seal," "liquid aerosol spray generator," and the pressure relationship between the oral cavity and nasal airway.

How strong is the patent estate for this technology?

The estate is strongest where the accused product closely reproduces the complete exhalation delivery architecture. Its strength is lower against products that separate the claimed functions among different components or use a different physiological mechanism.

Strength factors

The independent claims combine structural and functional limitations.
The claims are not limited to one active pharmaceutical ingredient.
The claims cover both device-only and device-plus-substance configurations.
Claim 14 captures feedback-enabled implementations.
The subject matter is linked to a commercial FDA-approved product.
Related continuation patents may provide additional claim scope.

Weakness factors

The claims require a specific combination of nasal sealing, aerosol generation, exhalation resistance, and pressure-induced velum closure.
Some limitations are functional and may invite indefiniteness or construction disputes.
A design-around may remove the oral flow resistor, alter the seal geometry, or use a different spray-actuation mechanism.
The combination claims may face prior-art challenges based on earlier nasal delivery systems combined with known inhalation-resistance techniques.

The patent is best characterized as a platform patent with meaningful but technically bounded claim scope. It is not a broad monopoly over nasal drug delivery.

How does US 9,072,857 compare with conventional nasal spray patents?

Issue	US 9,072,857	Conventional nasal spray patent
Primary subject	Delivery device	Formulation, spray pump, or treatment method
Patient action	Exhales against resistance	Usually inhales lightly or passively receives spray
Pressure control	Required	Usually absent
Nasal sealing	Required around outlet	Often absent or less specialized
Aerosol timing	During exhalation	Manual pump actuation
Cross-nasal flow	Covered in dependent claims	Usually not present
Active ingredient	Broad substance categories	Often ingredient-specific
Design-around route	Alter pressure, seal, resistor, or generator	Alter formulation, pump, or dose

A product can avoid conventional formulation patents yet still infringe a device patent if it uses the protected delivery architecture. Conversely, a product can replicate the active ingredient and indication without infringing US 9,072,857 if it uses a conventional spray system.

What generic entry risks exist?

Generic entry risk depends on whether a challenger must reproduce the Optinose delivery system to obtain the same regulatory product designation.

Higher-risk scenario for the patent owner

Risk is higher if a competitor seeks approval for:

The same exhalation delivery system.
The same or substantially similar nasal seal.
The same liquid aerosol generator.
The same exhalation flow resistor.
A device that provides audible or visual exhalation feedback.

Lower-risk scenario

Risk is lower if the competitor markets:

A conventional nasal pump.
A dry-powder nasal product.
A nebulized product with a different airway interface.
A product that does not require oral exhalation resistance.
A product with no pressure-supported velum closure.

The commercial consequence is that the patent may delay direct substitution for XHANCE without preventing all alternative fluticasone or intranasal corticosteroid products.

What licensing and collaboration issues are relevant?

Optinose’s commercial model has centered on proprietary exhalation delivery technology and product commercialization. Licensing analysis should distinguish between:

Rights to the device platform.
Rights to specific active ingredients.
Rights to formulations.
Rights to indications.
Rights to geographic markets.
Manufacturing rights for the delivery device.
Regulatory rights for approved products.

A license covering only the delivery platform may not include formulation patents or method-of-use patents. Conversely, a product license may include rights to manufacture or distribute XHANCE without conveying freedom to use the platform for unrelated drugs.

Public company filings, SEC agreements, and patent assignments are the principal sources for identifying documented licensing transactions and ownership changes.[3]

What manufacturing and IP barriers exist?

The main manufacturing barriers are not limited to the spray pump. A competing manufacturer may need to reproduce or replace:

The enlarged proximal sealing member.
The nasal outlet geometry.
The metered liquid aerosol generator.
The flow-resistance profile.
The pressure calibration between oral and nasal pathways.
The indicator system in claim 14.
Device-drug compatibility and dose uniformity.

FDA combination-product requirements can increase development risk because the drug formulation and delivery device must perform as an integrated system. Manufacturing changes may require comparability data, device-performance testing, dose-delivery testing, and human-factors validation.

What is the likely generic launch timeline?

The key dates are driven by the earliest effective patent filing date, FDA regulatory exclusivity, Orange Book listings, and any ANDA litigation.

Event	Commercial effect
Patent grant	Confirms enforceable claim set unless later invalidated
FDA approval	Establishes the reference product and potential Orange Book listing
Paragraph IV notice	Starts potential patent litigation
30-month stay	May delay ANDA approval
Patent expiration	Removes the patent-based exclusion right
Continuation patent expiration	May preserve later but narrower protection
Regulatory exclusivity expiration	Removes separate FDA approval barrier
Generic approval	Does not necessarily establish freedom to use all device patents

A generic launch can occur before all relevant patents expire if the applicant uses a noninfringing device, wins litigation, obtains a settlement right to launch, or faces no properly listed blocking patent.

Key Takeaways

US 9,072,857 is a platform patent for exhalation-actuated nasal delivery.
Claim 1 requires a specific combination of nasal sealing, liquid aerosol generation, exhalation resistance, and pressure-induced velum closure.
Claim 14 adds visual or audible feedback during exhalation.
Claims 8 through 13 extend the device to steroids, oxytocin, anti-migraine drugs, anti-allergic drugs, and anti-inflammatory drugs.
The patent is commercially relevant to Optinose’s XHANCE technology but is not limited to fluticasone propionate.
The expected base patent term is in the late 2020s, subject to the recorded priority chain and patent-term adjustment.
Generic risk is highest for products reproducing the exhalation delivery architecture and lower for conventional nasal sprays.
The principal litigation issues are likely to involve claim construction, obviousness, device equivalence, and whether the accused product creates the claimed oral-to-nasal pressure differential.
Related continuation, formulation, and method-of-use patents may be more important to final market exclusivity than US 9,072,857 alone.

FAQs

Is US 9,072,857 limited to XHANCE?

No. The claims cover a delivery-device platform and list multiple substance categories. XHANCE is a commercial implementation, but the patent is not expressly limited to fluticasone propionate.

Can a conventional fluticasone nasal spray infringe US 9,072,857?

Usually not if it lacks the claimed exhalation flow resistor, specialized nasal sealing member, and pressure-induced velum-closure architecture. The exact result depends on the device structure and claim construction.

Does the patent cover bilateral nasal delivery?

Yes, claims 5 through 7 address gas flow around the posterior nasal septum and an outlet unit fitted to the opposite nostril. The bilateral features are not required by claim 1.

Does US 9,072,857 protect the fluticasone formulation?

The supplied claims primarily protect the delivery device and device-substance combination. Separate formulation claims would be needed to protect fluticasone composition characteristics such as concentration, excipients, particle size, or spray performance.

Can a competitor avoid claim 14 by removing the indicator?

Potentially. Claim 14 requires a visual or audible signal during exhalation against the flow resistor. A device without that signal could still implicate claim 1, but it would not satisfy the added indicator limitation of claim 14.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
Optinose, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1292519
United States Patent and Trademark Office. (2015). Nasal delivery device, U.S. Patent No. 9,072,857 B2.
U.S. Food and Drug Administration. (2017). XHANCE, fluticasone propionate nasal spray: Prescribing information. Optinose, Inc.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9904906.6	Mar 3, 1999
United Kingdom	9911686.5	May 19, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	285810	⤷ Start Trial
Austria	422923	⤷ Start Trial
Austria	427130	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,072,857

Summary for Patent: 9,072,857